Paterson named GBC bioscience committee chair

The Greater Baltimore Committee today announced that Blake Paterson, M.D., founder and CEO of Alba Therapeutics, one of the fastest growing and most successful bioscience companies in the region, will chair the GBC’s Bioscience Committee.

Dr. Paterson was asked to chair the committee because of his experience with start-up bioscience companies, his acknowledged leadership in the industry and his interest in affecting legislation that will benefit bioscience companies in Maryland.

Dr. Paterson said, “There is a great deal of work to be done in the public policy arena in order to ensure the continued growth of our young regional bioscience industry. We will do that work through the GBC Bioscience Committee.” Under Dr. Paterson’s leadership, the group is working on a business case statement for bioscience to present to legislators as a public information vehicle.

Donald C. Fry, president and CEO of the Greater Baltimore Committee said, “We consider ourselves to be extremely fortunate to have one of the stars of the bioscience community as head of our committee. Alba Therapeutics has grown exponentially in five years under his leadership and has attracted the kind of investment capital that we want to see for all of our companies. His knowledge of the industry and what it takes to make it succeed is unparalleled.”

Prior to founding Alba in 2004, Dr. Paterson was Chief Operating Officer of Integrity Pharmaceutical Corporation. He also served as Executive Director, Oncology Acute Care and Inflammation Product Groups at Eli Lilly & Company, and was founder, Chairman and CEO of Arbor Research Corporation.

Dr. Paterson received his BS in Engineering from Tufts University and his M.D. from the University of Vermont. He completed his anesthesiology residency and fellowships in Critical Care Medicine and Cardio-Thoracic Anesthesia at Massachusetts General Hospital. Dr. Paterson is a Diplomat of the American Board of Anesthesiology.

The GBC Bioscience Committee includes members from the bioscience industry and from companies that routinely work with it as well as select academic members.

For more information, contact Lisbeth Pettengill at the Greater Baltimore Committee, 410-727-2820.

Comments are closed.